Syndax Pharmaceuticals, Inc. (SNDX) — Stock Score Summary

Syndax Pharmaceuticals, Inc. (SNDX) has a MoatMap StockRank of 19/100 based on Quality (15/100), Value (33/100), and Momentum (57/100) factor scores. The current signal is STRONG SELL. Syndax Pharmaceuticals is a clinical-stage biotech with high cash burn and binary trial risks, failing our Terry Smith quality compounder criteria.

Syndax Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing innovative therapies for cancer. Its pipeline includes differentiated small molecules and biologics targeting critical pathways in tumor biology and immune response, such as menin inhibition and CD73 blockade. Syndax's strong focus on unmet needs in difficult-to-treat cancers, coupled with its robust clinical development programs, positions it as a specialized player in the competitive oncology drug development landscape.

Key Financial Metrics

Price$18.34
Market Cap$1.8B
P/E (Forward)-38.29
Price/Book38.34
Return on Equity-189.5%
Return on Invested Capital-61.4%
Debt/Equity829.75
Gross Margin-23.2%
Operating Margin-52.7%
Revenue Growth223.6%
Free Cash Flow$-186M

Syndax Pharmaceuticals, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Syndax Pharmaceuticals, Inc.’s (SNDX) StockRank?
MoatMap’s StockRank for Syndax Pharmaceuticals, Inc. (SNDX) is 19/100, with a Strong Sell signal. It is a composite of Quality (15), Value (33), and Momentum (57) factor ranks across MoatMap’s 19,000+ stock universe.
Does Syndax Pharmaceuticals, Inc. have an economic moat?
Syndax Pharmaceuticals, Inc. (SNDX) has a Quality factor score of 15/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Syndax Pharmaceuticals, Inc. a buy, hold, or sell?
MoatMap’s current signal for Syndax Pharmaceuticals, Inc. (SNDX) is Strong Sell, based on a StockRank of 19/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Syndax Pharmaceuticals, Inc. in?
Syndax Pharmaceuticals, Inc. (SNDX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksSNDX deep dive reportAI ChampionsHow we score stocksSense-check another stock